This financing will sustain operations and programme development in neurodevelopmental disorders as Stalicla prepares for its upcoming Series C and the partnering of key programmes.
This financing underscores investor confidence in Stalicla’s innovative DEPI precision neuro platform and its portfolio of precision autism assets: STP1 and STP2.
The company is also progressing its STP7 (mavoglurant) programme, the most clinically advanced mGluR5 negative allosteric modulator, having concluded a Phase III enabling drug-drug interaction study in October 2024.
The Phase III development continues to be financed by National Institute of Health-National Institute on Drug Abuse (NIH-NIDA) under a Collaborative Research and Development Agreement.
As part of this financing, Tim Dyer has been appointed to the Board of Directors of Stalicla and nominated as Chair.
“This financing is a key step in securing our runway to reach several important milestones, including our Series C financing,” said Lynn Durham, CEO of Stalicla.
“We are grateful for the support from the Addex-led syndicate, which enables us to continue advancing our precision medicine programmes and prepare for transformative clinical trials in autism and substance use disorders.”
“Stalicla has built a world-leading precision medicine neurodevelopment disorder platform and portfolio of clinical-stage assets, as well as adding tremendous value to their Phase III-ready substance use disorders asset: STP7,” said Tim Dyer, CEO of Addex and Chair of Stalicla.
“We look forward to supporting Lynn Durham and her team as they bring these important medicines to patients.”
